Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115054
Chunk: 172

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 172
---
 or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this prospectus, we have not independently verified the market and industry data contained in this prospectus or the underlying assumptions relied on therein. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Notwithstanding the foregoing, we are liable for the information provided in this prospectus. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section of this prospectus titled “Risk Factors”. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

<div align='center'>103</div>

### USE OF PROCEEDS
We will only receive proceeds from the exercise of the 2024 Warrants if such warrants are exercised and the holders of such warrants pay the exercise price in cash upon such exercise and do not utilize the cashless exercise provision of the 2024 Warrants. We estimate that the gross proceeds to us from the exercise of the 2024 Warrants will be approximately $77.8 million, to the extent the exercise prices therefor are paid in cash.

We will not receive any proceeds from the resale pursuant to this prospectus of the Resale Shares obtained upon the exercise of the Deposit Warrant by the Selling Securityholder. We estimate that the gross proceeds to us from the exercise of the Deposit Warrant will be approximately $3.9 million.

We currently intend to use the proceeds (if any) from the exercise of the 2024 Warrants and the Deposit Warrant for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock.

The precise amount and timing of the application of these proceeds will depend upon a number of factors, such as the costs and timing of commercial and development activities, including, for example, conducting preclinical studies and clinical trials, our funding requirements and the availability and costs of other funds. Pending application of the proceeds as described above, we intend to temporarily invest the proceeds in interest-bearing instruments.

<div align='center'>104</div>

### DETERMINATION